PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
Feature|Videos|April 14, 2026 (Updated: April 23, 2026)
Beyond the Excipient: Drug Formulation from Discovery Through Commercialization
Author(s)Paul Smaltz, BASF
Key Takeaways
- Learn how to overcome complex formulation challenges, such as bioavailability and solubility, by leveraging the technical expertise of your excipient suppliers.
- Understand how BASF’s Virtual Pharma Assistants help customers formulate faster.
Paul Smaltz, Senior Vice President of BASF Pharma Solutions, explains how the company acts as a strategic partner to the pharmaceutical industry by integrating AI-driven formulation tools, sustainability initiatives, and specialized biopharmaceutical solutions to overcome modern manufacturing challenges.
As the pharmaceutical landscape shifts toward asset-light models and increased outsourcing, BASF is evolving beyond its role as a traditional excipient manufacturer to provide deep technical expertise and R&D support. Through the implementation of generative AI and the ZoomLab® predictive modeling tool, BASF is helping customers accelerate formulation timelines and solve complex bioavailability issues with unprecedented precision. Smaltz also discusses the BASF commitment to "green transformation," pointing to the company’s goal of reaching net-zero emissions by 2050 while delivering high-performance and sustainable solutions for the growing biopharmaceutical market.
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Trending on Pharmaceutical Technology
1
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
2
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
3
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
4
What the Olanzapine Depot Approval Means for CMC Teams
5